Aug 14 (Reuters) - Dental implant maker Straumann announced the sale of its DrSmile aligner business and raised its full-year outlook to reflect that on Wednesday, even as it reported a slight miss in second-quarter sales.

The company said it had signed an agreement to sell DrSmile to Barcelona-based clear aligner provider Impress Group. Straumann said it would receive a minority stake of 20% in the combined entity, without disclosing other financial details of the deal.

Following the sale, the Swiss company will focus even more on its go-to-market activities in the orthodontics business-to-business area, it added.

Straumann, which specialises in tooth replacement and orthodontic solutions, forecast 2024 organic revenue growth in a low double-digit percentage range, with profitability of 27-28% at constant 2023 currency rates. It had previously expected high single-digit organic growth and profitability of around 26%.

Group revenue grew 14.8% organically in the second quarter to 654.9 million Swiss francs ($757.1 million), slightly below analysts' expectations of 659.6 million francs in a poll compiled by Vara. ($1 = 0.8650 Swiss francs) (Reporting by Marleen Kaesebier and Isabel Demetz in Gdansk; editing by Milla Nissi)